Marlborough pharma announces clinical trial
Courtesy of RXi Pharmaceuticals Corp.
RXi Pharmaceuticals Corporation announced this week a phase 2 clinical trial to evaluate the safety and clinical activity of Samcyprone, an immunomodulator that could help clear cutaneous warts.
The Marlborough-based biotechnology company, which finalized an exclusive global license for the drug in February, will carry out the multi-dose, multi-center trial on people with at least one cutaneous, plantar or periungual wart for a least four weeks.
During the trial, subjects will receive a sensation dose on their inner arm and on a wart, and once a response is confirmed, they will be treated weekly for 10 weeks. Progress will be tracked based on the Investigator’s Global Assessment Score and wart measurements over the course of treatment.
The warts, caused by human papillomaviruses (HPV), are very common, and most people get one at some point in their lives. Treatment, however, typically isn’t successful and can lead to prolonged therapy and the potential for recurrence. Cell-mediated immune response has been proven to control HPV infections, so immunotherapy has been used to activate the immunologic response to HPV.
A previous proof of concept trial of Samcyprone from Hapten Pharmaceuticals, LLC found the drug to be safe and that it was a good wart treatment compared to placebo.
WBJ Web Partners
Most Recent
Most Recent
0 Comments